Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VIVO Meridian Bioscience (VIVO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Meridian Bioscience Stock (NASDAQ:VIVO) 30 days 90 days 365 days Advanced Chart Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Meridian Bioscience alerts:Sign Up Key Stats Today's Range$33.97▼$33.9750-Day Range$33.00▼$33.9752-Week Range$20.35▼$34.38VolumeN/AAverage Volume973,737 shsMarket Capitalization$1.50 billionP/E Ratio35.02Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMeridian Bioscience, Inc. engages in the development, production, sale, and distribution of diagnostic products. Its platforms include molecular, immunoassay, urea breath, and blood chemistry. It operates through the Diagnostics and Life Science segments. The Diagnostics segment consists of manufacturing operations for infectious disease and blood chemistry products and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment distributes bulk antigens, antibodies, polymerase chain reaction/ quantitative PCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded by William J. Motto in 1976 and is headquartered in Cincinnati, OH.Read More… Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Meridian Bioscience Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks21st Percentile Overall ScoreVIVO MarketRank™: Meridian Bioscience scored higher than 21% of companies evaluated by MarketBeat, and ranked 873rd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Meridian Bioscience. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Meridian Bioscience is 35.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 127.15.Price to Earnings Ratio vs. SectorThe P/E ratio of Meridian Bioscience is 35.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 94.60.Price to Book Value per Share RatioMeridian Bioscience has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for VIVO. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMeridian Bioscience does not currently pay a dividend.Dividend GrowthMeridian Bioscience does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.88 Short InterestThere is no current short interest data available for VIVO. News and Social Media0.6 / 5News SentimentN/A Search Interest6 people have searched for VIVO on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Meridian Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.30% of the stock of Meridian Bioscience is held by insiders.Percentage Held by Institutions89.72% of the stock of Meridian Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Meridian Bioscience's insider trading history. Receive VIVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address VIVO Stock News HeadlinesMeridian Bioscience Awarded Bronze Medal by EcoVadis for the Second Consecutive Year in Recognition of Its Continued Dedication to SustainabilityNovember 7, 2024 | finance.yahoo.comWill iQOO 13 launch at same price as iQOO 12? New leak provides major hintOctober 25, 2024 | msn.comTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.November 21, 2024 | Weiss Ratings (Ad)Meridian Growth Legacy MERDXOctober 17, 2024 | morningstar.comVivo V40 vs Realme GT 6T: How the two mid-range smartphones compareAugust 11, 2024 | msn.comMeridian Bioscience Leads the Way with Innovative Sustainable Solutions for in vitro Diagnostic ManufacturersJuly 23, 2024 | finance.yahoo.comBiomerica, Inc. (BMRA)May 11, 2024 | finance.yahoo.comMeridian Meadows Transitional CareFebruary 8, 2024 | health.usnews.comSee More Headlines VIVO Stock Analysis - Frequently Asked Questions How were Meridian Bioscience's earnings last quarter? Meridian Bioscience, Inc. (NASDAQ:VIVO) issued its earnings results on Friday, November, 12th. The company reported $0.24 earnings per share for the quarter, beating analysts' consensus estimates of $0.21 by $0.03. The business earned $76.20 million during the quarter, compared to analyst estimates of $68.40 million. Meridian Bioscience had a trailing twelve-month return on equity of 16.74% and a net margin of 12.70%. Does Meridian Bioscience have any subsidiaries? Meridian Bioscience subsidiaries include Exalenz Bioscience. What other stocks do shareholders of Meridian Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Meridian Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), PayPal (PYPL), Micron Technology (MU) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings11/12/2021Today11/21/2024Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:VIVO CUSIP58958410 CIK794172 Webwww.meridianbioscience.com Phone(513) 271-3700Fax513-271-3762Employees702Year Founded1977Profitability EPS (Most Recent Fiscal Year)$0.97 Trailing P/E Ratio35.02 Forward P/E Ratio40.93 P/E GrowthN/ANet Income$42.46 million Net Margins12.70% Pretax Margin16.31% Return on Equity16.74% Return on Assets13.09% Debt Debt-to-Equity Ratio0.07 Current Ratio3.63 Quick Ratio2.46 Sales & Book Value Annual Sales$333.02 million Price / Sales4.49 Cash Flow$1.78 per share Price / Cash Flow19.13 Book Value$8.41 per share Price / Book4.04Miscellaneous Outstanding Shares44,010,000Free Float42,996,000Market Cap$1.50 billion OptionableOptionable Beta0.23 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report This page (NASDAQ:VIVO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Meridian Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Meridian Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.